Safety and Tolerability of PCSK9 Inhibitors: Current Insights
Constantine E Kosmas,1 Andreas Skavdis,2 Andreas Sourlas,3 Evangelia J Papakonstantinou,4 Edilberto Peña Genao,5 Rogers Echavarria Uceta,5 Eliscer Guzman1 1Division of Cardiology, Department of Medicine, Montefiore Medical Center, Bronx, NY, USA; 2School of Medicine, University of Athens,...
Enregistré dans:
Auteurs principaux: | Kosmas CE, Skavdis A, Sourlas A, Papakonstantinou EJ, Peña Genao E, Echavarria Uceta R, Guzman E |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2020
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/817a135acf6143918c3328e778e3ad40 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential
par: Kosmas CE, et autres
Publié: (2020) -
A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects
par: Liu C, et autres
Publié: (2019) -
Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players
par: Patrice Marques, et autres
Publié: (2022) -
Effects of immunisation against PCSK9 in mice bearing melanoma
par: Amir Abbas Momtazi-Borojeni, et autres
Publié: (2019) -
PCSK9 Gene Polymorphisms Associated With the Risk of Myocardial Infarction in Iranian Patients
par: Farshad Namordizadeh, et autres
Publié: (2021)